AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2019
Jan 23, 2019
31580_dirs_2019-01-23_2a9b3813-2733-4a84-92c4-70e594e6a38a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2019-01-20
Reporting Person: Hirsch Andrew (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-01-20 | Common stock | M | 15000 | — | Acquired | 15000 | Direct |
| 2019-01-22 | Common stock | F | 4555 | $52.82 | Disposed | 10445 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-01-20 | Performance share unit | $ | M | 15000 | Disposed | Common stock (15000) | Direct |
Footnotes
F1: Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
F2: The performance share units were originally granted on September 20, 2016. The performance share units vest in full six months after the achievement of performance milestone. Performance milestone was achieved on July 20, 2018, and the performance share will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.